A 10 Week, Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg qd) to Twice Daily Dosing of Aliskiren (150 mg Bid) in Patients With Essential Hypertension.
Phase of Trial: Phase IV
Latest Information Update: 04 Feb 2015
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 14 Jun 2011 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2008 New trial record.